Sweta Shah, MD
Allergy & Immunology · Metairie, LANPI 1902197403
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 402 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,030 and has fallen 84.1% since, to $323 in 2025.
Across 402 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$1K
- AstraZeneca$983
- Pfizer$813
- GSK$776
- CSL Behring$741
- Sanofi$587
- plus $3K from 26 others
What the payments were for
- Food & beverage$7,473100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 58 | $1,007 |
| AstraZeneca | 58 | $983 |
| Pfizer | 39 | $813 |
| GSK | 51 | $776 |
| CSL Behring | 31 | $741 |
| Sanofi | 26 | $587 |
| Grifols USA, LLC | 33 | $583 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $325 |
| Optinose US, Inc. | 13 | $209 |
| Novartis | 10 | $201 |
| Bio Products Laboratory USA, Inc. | 11 | $152 |
| Genentech USA, Inc. | 6 | $134 |
| Alk-abello, Inc | 7 | $110 |
| AbbVie | 6 | $108 |
| Amgen | 6 | $103 |
| Boehringer Ingelheim | 6 | $103 |
| Octapharma USA, Inc. | 4 | $80 |
| LEO Pharma Inc. | 4 | $68 |
| Kaleo, Inc. | 4 | $67 |
| Blueprint Medicines Corporation | 1 | $52 |
| Biocryst US Sales Co., LLC | 2 | $40 |
| ADMA Biomanufacturing LLC | 2 | $38 |
| Hikma Pharmaceuticals USA | 2 | $36 |
| Lilly USA, LLC | 1 | $27 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $26 |
| Shire North American Group Inc | 1 | $23 |
| Incyte Corporation | 1 | $21 |
| USWM, LLC | 1 | $21 |
| Biocryst Pharmaceuticals, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Merck | 1 | $14 |
| Greer Laboratories, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EUCRISA$125
How this compares
$7,493 in reported general payments places this provider in the 75th percentile of 62 allergy & immunology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 74 | $287,018 |
| Gammagard S-DImmun Glob G/Gly/Gluc/Iga 0-50 | 12 | $110,336 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $46,009 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 14 | $24,307 |
| Epinephrine | 27 | $6,654 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,171 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,458 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $2,163 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 44 | $908 |
| Levocetirizine Dihydrochloride | 83 | $843 |
| Fluticasone Propionate | 62 | $770 |
| Famotidine | 28 | $407 |
| Montelukast Sodium | 45 | $270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $776 | $52,18068 claims |
| Grifols USA, LLCGamunex-C | $583 | $24,30714 claims |
| Hikma Pharmaceuticals USAEpinephrine | $36 | $6,65427 claims |
| AstraZenecaSymbicort | $983 | $3,45815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 62 allergy & immunology providers in Louisiana.
Other allergy & immunology in Metairie
- Sarah QayumMetairie$11K
- David SchneiderMetairie$10K
- Jeffery FranklinMetairie$9K
- Alice HoytMetairie$7K
- Tammy HarveyMetairie$7K
- Alan SheenMetairie$4K
- David KaufmanShreveport$678K
- Reena MehtaNew Orleans$159K
- Kenneth ParisNew Orleans$150K
- Brice RolstonCovington$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.